To promote patient safety and ensure the safest possible use of all biologics, including biosimilars, the Biologics Prescribers Collaborative is aligned on the following guiding principles:

  1. Considering the often debilitating or even life-threatening conditions experienced by people who regularly use biologics, all biosimilars-focused policy decisions should seek to, above all else, promote patient safety and preserve the patient-physician relationship.

  2. Distinguishable names for all biologic products, including biosimilars, are imperative to promote patient safety, strengthen patient-physician communication and enhance confidence in these vital medicines.

  3. Clear, active prescriber-pharmacist communication should occur in the event that an interchangeable biosimilar is substituted.

  4. Dispense as Written (DAW) authority should be used for specific clinical reasons for patient care; it should not have to be used as a fix for legislation that neglects to promote effective access to a patient’s medication history.